Researchers from the Djavad Mowafaghian Centre for Brain Health (DMCBH) are among the recipients of a major new investment supporting Alzheimer’s and Parkinson’s disease research in British Columbia. DMCBH members are leading or co-leading all six projects selected through the Advancing Groundbreaking Research in Alzheimer’s and Parkinson’s Diseases Team Award, a $3-million initiative created by Michael Smith Health Research BC and supported by eight funding partners.
The announcement was celebrated today at a gathering of researchers, community members and funding partners at the DMCBH, recognizing the teams’ contributions to advancing understanding, diagnosis and treatment of neurodegenerative diseases.
The six projects bring together expertise spanning neuroscience, biomarkers, artificial intelligence, digital health and clinical research. Their work addresses important challenges in neurodegenerative diseases, from identifying earlier and more accessible diagnostic tools to improving treatment approaches and supporting people living with these conditions.
Congratulations to the DMCBH researchers and their collaborators on this achievement and the important work ahead.
Meet the funded research teams
A blood test for earlier detection of Parkinson’s disease
Primary applicant: Shyh-Dar Li
Co-leads: Silke Appel-Cresswell, Sam Fereshtehnejad
There is currently no reliable blood test for early detection or monitoring treatment response in Parkinson’s disease. This team is investigating a promising biomarker associated with disease severity and exploring whether it could form the basis of a blood test to support earlier detection and improve the evaluation of new treatments. Learn more
Exploring the gut-brain connection in Alzheimer’s disease
Primary applicant: Annie Ciernia
Collaborators: Khaled Abdelrahman, Xin Tang
People with chronic gut inflammation face a higher risk of developing Alzheimer’s disease. Using mouse models, this team is investigating how gut bacteria influence brain health, including memory, brain inflammation, blood flow and the accumulation of proteins associated with Alzheimer’s disease. Learn more
Improving precision in Parkinson’s disease treatment
Primary applicant: Alexander Rauscher
Co-lead: Stefan Lang
Collaborator: Martin McKeown
Deep brain stimulation can help manage Parkinson’s symptoms, but accurate electrode placement is essential for treatment success. This team is refining MRI imaging approaches to improve the precision of electrode placement, with the goal of enhancing symptom control while making the procedure faster and more comfortable for patients. Learn more
Bringing Parkinson’s monitoring into the home
Primary applicant: Martin McKeown
Changes in Parkinson’s symptoms can be difficult to track between clinical appointments. This team is developing and testing an at-home digital monitoring system that provides patients and clinicians with real-time insights into disease progression. The technology aims to support patient safety, inform care decisions and strengthen communication between patients and their healthcare teams. Learn more
Improving diagnosis of Lewy body disease
Primary applicant: Robin (Ging-Yuek) Hsiung
Co-lead: Cheryl Wellington
Co-investigators: Silke Appel-Cresswell, Ian Mackenzie
Lewy body disease shares characteristics with both Alzheimer’s and Parkinson’s, making diagnosis challenging. This team is investigating the similarities and differences between these conditions to develop a blood test that could help distinguish them, supporting earlier and more accurate diagnoses and timely access to appropriate care. Learn more
Exploring tears as a potential biomarker for Alzheimer’s disease
Primary applicant: Joanne Matsubara
Co-Lead: Robin (Ging-Yuek) Hsiung
Early detection of Alzheimer’s remains challenging, and researchers are exploring more accessible ways to identify signs of disease. This team is investigating whether tears could provide a non-invasive source of biomarkers for Alzheimer’s, building on the connection between the eye and the central nervous system. Learn more
Advancing brain health through collaboration
The $3-million investment is made possible through the Canada Brain Research Fund, an innovative arrangement between the Government of Canada, through Health Canada, and Brain Canada Foundation. Together in partnership with the Alzheimer Society of BC, Branch Out Neurological Foundation, CLEAR Foundation, Health Research BC, Pacific Parkinson’s Research Institute, Parkinson Society BC, and the Patrick & Dulcie Lenox Endowment, this iniaitive advances meaningful solutions for BC’s aging population and strengthening networks between researchers, partners, and research users.
The success of all six funded teams highlights the strength and breadth of neurodegenerative disease research at the DMCBH and our members’ leadership in advancing brain health research in BC.


